Guideline directed medical therapy induced nephrotoxicity in HFrEF patients; an insight to its mechanism

References

• Al‐Naher, A., Wright, D., Devonald, M. A., & Pirmohamed, M. (2018). Renal function monitoring in heart failure–what is the optimal frequency? A narrative review. British Journal of Clinical Pharmacology, 84(1), 5–17. https://doi.org/10.1111/bcp.13434
   PubMed Web of Science ®Google Scholar
• Al-Naimi, M. S., Rasheed, H. A., Hussien, N. R., Al-Kuraishy, H. M., & Al-Gareeb, A. I. (2019). Nephrotoxicity: Role and significance of renal biomarkers in the early detection of acute renal injury. Journal of Advanced Pharmaceutical Technology & Research, 10(3), 95–99. https://doi.org/10.4103/japtr.JAPTR_336_18
   PubMed Web of Science ®Google Scholar
• Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., Bocchi, E. A., Ponikowski, P., Perrone, S. V., Januzzi, J. L., Verma, S., Böhm, M., Ferreira, J. P., Pocock, S. J., Zannad, F., & Packer, M. (2021). Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: Results from the EMPEROR-reduced trial. Circulation, 143(4), 337–349. https://doi.org/10.1161/CIRCULATIONAHA.120.051824
   PubMed Web of Science ®Google Scholar
• Bauersachs, J. (2021). Heart failure drug treatment: The fantastic four. European Heart Journal, 42(6), 681–683. https://doi.org/10.1093/eurheartj/ehaa1012
   PubMed Web of Science ®Google Scholar
• Beldhuis, I. E., Lam, C. S. P., Testani, J. M., Voors, A. A., Van Spall, H. G. C., Ter Maaten, J. M., & Damman, K. (2022). Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation, 145(9), 693–712. https://doi.org/10.1161/CIRCULATIONAHA.121.052792
   PubMed Web of Science ®Google Scholar
• Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Cassarino, T. G., Bertoni, M., Bordoli, L., & Schwede, T. (2014). SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Research, 42(Web Server issue), W252–8. https://doi.org/10.1093/nar/gku340
   PubMed Web of Science ®Google Scholar
• Bode, D., Semmler, L., Wakula, P., Hegemann, N., Primessnig, U., Beindorff, N., Powell, D., Dahmen, R., Ruetten, H., Oeing, C., Alogna, A., Messroghli, D., Pieske, B. M., Heinzel, F. R., & Hohendanner, F. (2021). Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF. Cardiovascular Diabetology, 20(1), 7. https://doi.org/10.1186/s12933-020-01208-z
   PubMed Web of Science ®Google Scholar
• Chaturvedi, V., Parakh, N., Seth, S., Bhargava, B., Ramakrishnan, S., Roy, A., Saxena, A., Gupta, N., Misra, P., Rai, S., Anand, K., Pandav, C., Sharma, R., & Prasad, S. (2016). Heart failure in India: The INDUS (INDia ukieri study) study. Journal of the Practice of Cardiovascular Sciences, 2(1), 28–35. https://doi.org/10.4103/2395-5414.182988
   Google Scholar
• Corredor, Z., Filho, M. I. D. S., Rodríguez-Ribera, L., Velázquez, A., Hernández, A., Catalano, C., Hemminki, K., Coll, E., Silva, I., Diaz, J. M., Ballarin, J., Vallés-Prats, M., Calabia-Martínez, J., Försti, A., Marcos, R., & Pastor, S. (2020). Genetic variants associated with chronic kidney disease in a Spanish population. Scientific Reports, 10(1), 144. https://doi.org/10.1038/s41598-019-56695-2
   PubMedGoogle Scholar
• Cowie, M. R., & Fisher, M. (2020). SGLT-2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews. Cardiology, 17(12), 761–772. https://doi.org/10.1038/s41569-020-0406-8
   PubMed Web of Science ®Google Scholar
• Deshpande, N. S., Dwivedi, P. S. R., & Revanasiddappa, B. C. (2023). Virtual screening, pharmacokinetics & MD simulation study of active phytoconstituents of Ficus Carica Linn. against PPAR-γ in diabetes mellitus. Journal of Biomolecular Structure & Dynamics, 1–17. https://doi.org/10.1080/07391102.2023.2279286
   Google Scholar
• Dixit, N., Shah, S., Ziaeian, B., Fonarow, G., & Hsu, J. (2021). Optimizing guideline-directed medical therapies for heart failure with reduced ejection fraction during hospitalization. US Cardiology Review, 15, e07. https://doi.org/10.15420/usc.2020.29
   Google Scholar
• Dwivedi, P. S. R., & Shastry, C. S. (2023). The cytotoxic potential of sinapic acid on luminal A breast cancer; a computational and experimental pharmacology approach. Journal of Biomolecular Structure & Dynamics, 1–16. https://doi.org/10.1080/07391102.2023.2274980
   Web of Science ®Google Scholar
• Dwivedi, P. S. R., Patil, R., Khanal, P., Gurav, N. S., Murade, V. D., Hase, D. P., Kalaskar, M. G., Ayyanar, M., Chikhale, R. V., & Gurav, S. S. (2021a). Exploring the therapeutic mechanisms of Cassia glauca in diabetes mellitus through network pharmacology, molecular docking and molecular dynamics. RSC Advances, 11(62), 39362–39375. https://doi.org/10.1039/d1ra07661b
   PubMed Web of Science ®Google Scholar
• Dwivedi, P. S. R., Patil, V. S., Khanal, P., Bhandare, V. V., Gurav, S., Harish, D. R., Patil, B. M., & Roy, S. (2022). System biology-based investigation of Silymarin to trace hepatoprotective effect. Computers in Biology and Medicine, 142, 105223. https://doi.org/10.1016/j.compbiomed.2022.105223
   PubMed Web of Science ®Google Scholar
• Dwivedi, P. S. R., Rasal, V. P., Kotharkar, E., Nare, S., & Khanal, P. (2021b). Gene set enrichment analysis of PPAR-γ regulators from Murraya odorata Blanco. Journal of Diabetes and Metabolic Disorders, 20(1), 369–375. https://doi.org/10.1007/s40200-021-00754-x
   PubMed Web of Science ®Google Scholar
• Esmaeeli, A., Keshavarz, Z., Dehdar, F., Assadi, M., & Seyedabadi, M. (2022). The effects of carvedilol, metoprolol and propranolol on cisplatin-induced kidney injury. Drug and Chemical Toxicology, 45(4), 1558–1564. https://doi.org/10.1080/01480545.2020.1846551
   PubMed Web of Science ®Google Scholar
• Halgren, T. A. (1999). MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. Journal of Computational Chemistry, 20(7), 730–748. https://doi.org/10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T
   PubMed Web of Science ®Google Scholar
• Herbst, A., Orso, F., Migliorini, M., Virciglio, S., Tognelli, S., Camartini, V., Pratesi, A., Fattirolli, F., Marchionni, N., Ungar, A., & Baldasseroni, S. (2020). ARNI and SGLT-2i: A promising association to be used with caution. Journal of Geriatric Cardiology, 17(11), 728–732. https://doi.org/10.11909/j.issn.1671-5411.2020.11.005
   Web of Science ®Google Scholar
• Huang, J., & MacKerell, A. D. (2013). CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. Journal of Computational Chemistry, 34(25), 2135–2145. https://doi.org/10.1002/jcc.23354
   PubMed Web of Science ®Google Scholar
• Huang, J., Rauscher, S., Nawrocki, G., Ran, T., Feig, M., de Groot, B. L., Grubmüller, H., & MacKerell, A. D. (2017). CHARMM36m: An improved force field for folded and intrinsically disordered proteins. Nature Methods, 14(1), 71–73. https://doi.org/10.1038/nmeth.4067
   PubMed Web of Science ®Google Scholar
• Huber, T. B., Edelstein, C. L., Hartleben, B., Inoki, K., Jiang, M., Koya, D., Kume, S., Lieberthal, W., Pallet, N., Quiroga, A., Ravichandran, K., Susztak, K., Yoshida, S., & Dong, Z. (2012). Emerging role of autophagy in kidney function, diseases and aging. Autophagy, 8(7), 1009–1031. https://doi.org/10.4161/auto.19821
   PubMed Web of Science ®Google Scholar
• Jerotic, D., Matic, M., Suvakov, S., Vucicevic, K., Damjanovic, T., Savic-Radojevic, A., Pljesa-Ercegovac, M., Coric, V., Stefanovic, A., Ivanisevic, J., Jelic-Ivanovic, Z., McClements, L., Dimkovic, N., & Simic, T. (2019). Association of Nrf2, SOD2 and GPX1 polymorphisms with biomarkers of oxidative distress and survival in end-stage renal disease patients. Toxins, 11(7), 431. https://doi.org/10.3390/toxins11070431
   PubMed Web of Science ®Google Scholar
• Khanal, P., Dwivedi, P. S. R., Patil, V. S., Shetty, A., S, A., Aga, A., R, A., Javaid, A., & Bhandare, V. V. (2023). Barosmin against postprandial hyperglycemia: Outputs from computational prediction to functional responses in vitro. Journal of Biomolecular Structure & Dynamics, 105668, 1–17. https://doi.org/10.1080/07391102.2023.2233631
   Google Scholar
• Khanal, P., Patil, V. S., Bhandare, V. V., Dwivedi, P. S. R., Shastry, C. S., Patil, B. M., Gurav, S. S., Harish, D. R., & Roy, S. (2022). Computational investigation of benzalacetophenone derivatives against SARS-CoV-2 as potential multi-target bioactive compounds. Computers in Biology and Medicine, 146, 105668. https://doi.org/10.1016/j.compbiomed.2022.105668
   PubMed Web of Science ®Google Scholar
• Kimura, T., Takabatake, Y., Takahashi, A., Kaimori, J. Y., Matsui, I., Namba, T., Kitamura, H., Niimura, F., Matsusaka, T., Soga, T., Rakugi, H., & Isaka, Y. (2011). Autophagy protects the proximal tubule from degeneration and acute ischemic injury. Journal of the American Society of Nephrology: JASN, 22(5), 902–913. https://doi.org/10.1681/ASN.2010070705
   PubMed Web of Science ®Google Scholar
• Kumar, K. V., Shifow, A. A., Naidu, M. U., & Ratnakar, K. S. (2000). Carvedilol: A β blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sciences, 66(26), 2603–2611. https://doi.org/10.1016/s0024-3205(00)00594-4
   PubMed Web of Science ®Google Scholar
• Lagunin, A., Ivanov, S., Rudik, A., Filimonov, D., & Poroikov, V. (2013). DIGEP-Pred: Web service for in silico prediction of drug-induced gene expression profiles based on structural formula. Bioinformatics (Oxford, England), 29(16), 2062–2063. https://doi.org/10.1093/bioinformatics/btt322
   PubMed Web of Science ®Google Scholar
• Lahoz, R., Fagan, A., McSharry, M., Proudfoot, C., Corda, S., & Studer, R. (2020). Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink. ESC Heart Failure, 7(4), 1688–1699. https://doi.org/10.1002/ehf2.12727
   PubMed Web of Science ®Google Scholar
• López-Blanco, J. R., Aliaga, J. I., Quintana-Ortí, E. S., & Chacón, P. (2014). iMODS: Internal coordinates normal mode analysis server. Nucleic Acids Research, 42(Web Server issue), W271–6. https://doi.org/10.1093/nar/gku339
   PubMed Web of Science ®Google Scholar
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C. E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., … Langkilde, A. M, DAPA-HF Trial Committees and Investigators. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Mordi, N. A., Mordi, I. R., Singh, J. S., McCrimmon, R. J., Struthers, A. D., & Lang, C. C. (2020). Renal and cardiovascular effects of SGLT-2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: The RECEDE-CHF trial. Circulation, 142(18), 1713–1724. https://doi.org/10.1161/CIRCULATIONAHA.120.048739
   PubMed Web of Science ®Google Scholar
• Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020). Heart failure with reduced ejection fraction: A review. JAMA, 324(5), 488–504. https://doi.org/10.1001/jama.2020.10262
   PubMed Web of Science ®Google Scholar
• Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., Drazner, M. H., Fong, M. W., Givertz, M. M., Gordon, R. A., Jermyn, R., Katz, S. D., Lamba, S., Lanfear, D. E., LaRue, S. J., … Kosiborod, M. (2019). Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: The DEFINE-HF Trial. Circulation, 140(18), 1463–1476. https://doi.org/10.1161/CIRCULATIONAHA.119.042929
   PubMed Web of Science ®Google Scholar
• Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C. E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., Howlett, J., Katova, T., Kitakaze, M., Ljungman, C. E. A., … McMurray, J. J. V. (2020). Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA, 323(14), 1353–1368. https://doi.org/10.1001/jama.2020.1906
   PubMed Web of Science ®Google Scholar
• Piñero, J., Bravo, À., Queralt-Rosinach, N., Gutiérrez-Sacristán, A., Deu-Pons, J., Centeno, E., García-García, J., Sanz, F., & Furlong, L. I. (2017). DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Research, 45(D1), D833–D839. https://doi.org/10.1093/nar/gkw943
   PubMed Web of Science ®Google Scholar
• Poleksic, A., & Xie, L. (2019). Database of adverse events associated with drugs and drug combinations. Scientific Reports, 9(1), 20025. https://doi.org/10.1038/s41598-019-56525-5
   PubMedGoogle Scholar
• Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., & Marzocco, S. (2019). Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals, vitamins and plant-derived metabolites. International Journal of Molecular Sciences, 21(1), 263. https://doi.org/10.3390/ijms21010263
   PubMed Web of Science ®Google Scholar
• Rossignol, P., Hernandez, A. F., Solomon, S. D., & Zannad, F. (2019). Heart failure drug treatment. Lancet (London, England), 393(10175), 1034–1044. https://doi.org/10.1016/S0140-6736(18)31808-7
   PubMed Web of Science ®Google Scholar
• Savarese, G., & Lund, L. H. (2017). Global public health burden of heart failure. Cardiac Failure Review, 3(1), 7–11. https://doi.org/10.15420/cfr.2016:25:2
   PubMedGoogle Scholar
• Savarese, G., Stolfo, D., Sinagra, G., & Lund, L. H. (2022). Heart failure with mid-range or mildly reduced ejection fraction. Nature Reviews. Cardiology, 19(2), 100–116. https://doi.org/10.1038/s41569-021-00605-5
   PubMed Web of Science ®Google Scholar
• Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Research, 13(11), 2498–2504. https://doi.org/10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Shoar, S., Shah, A. A., Ikram, W., Farooq, N., Udoh, A., Tabibzadeh, E., Khavandi, S., & Khavandi, S. (2021). Cardiovascular benefits of SGLT-2 inhibitors in patients with heart failure: A meta-analysis of small and large randomized controlled trials. American Journal of Cardiovascular Disease, 11(3), 262–272.
   PubMed Web of Science ®Google Scholar
• Spoel, D. V., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N. T., Legeay, M., Fang, T., Bork, P., Jensen, L. J., & von Mering, C. (2021). The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Research, 49(D1), D605–D612. Erratum in: Nucleic Acids Research, 49(18), (2021) 10800. https://doi.org/10.1093/nar/gkaa1074
   PubMed Web of Science ®Google Scholar
• Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A., & Moreno, E. (2021). gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. Journal of Chemical Theory and Computation, 17(10), 6281–6291. https://doi.org/10.1021/acs.jctc.1c00645
   PubMed Web of Science ®Google Scholar
• Verma, S., & McMurray, J. J. (2018). SGLT-2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia, 61(10), 2108–2117. https://doi.org/10.1007/s00125-018-4670-7
   PubMed Web of Science ®Google Scholar
• Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J. M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, I., Di Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F. D. R., Hollander, M., … Williams, B, ESC Scientific Document Group. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(34), 3227–3337. Erratum in: European Heart Journal, 43(42) (2022) 4468. https://doi.org/10.1001/jama.2020.1906 https://doi.org/10.1093/eurheartj/ehab484
   PubMed Web of Science ®Google Scholar
• Wang, R. S., Maron, B. A., & Loscalzo, J. (2015). Systems medicine: Evolution of systems biology from bench to bedside. Wiley Interdisciplinary Reviews. Systems Biology and Medicine, 7(4), 141–161. https://doi.org/10.1002/wsbm.1297
   PubMed Web of Science ®Google Scholar
• Zeier, M. (2018). ACE inhibitors and ARB in chronic kidney disease: what has to be considered. Deutsche Medizinische Wochenschrift (1946), 143(12), 880–885. https://doi.org/10.1055/a-0549-9662
   PubMed Web of Science ®Google Scholar
• Zheng, C.-M., Wang, J.-Y., Chen, T.-T., Wu, Y.-C., Wu, Y.-L., Lin, H.-T., Chiu, S.-P., Chang, T.-J., Zheng, J.-Q., Chu, N.-F., Lin, Y.-M., Su, S.-L., Lu, K.-C., Chen, J.-S., Sung, F.-C., Lee, C.-T., Yang, Y., Hwang, S.-J., Wang, M.-C., … Lin, Y.-F. (2019). Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population. Scientific Reports, 9(1), 2694. https://doi.org/10.1038/s41598-019-38991-z
   PubMedGoogle Scholar